通痹合剂对冠心病心绞痛患者血清TNF-α、IL-6的影响_论文.docVIP

摘  要  目的 观察通痹合剂对冠心病心绞痛患者血清中肿瘤坏死因子- a (TNF- a)白介素-6（IL-6）水平的影响，阐述该方改善心血管危险因素，多环节、 多靶位治疗冠心病心绞痛患者，讨论中医在治疗冠心病的作用机制。 方法 本试验采用临床观察与理论研究相结合的方法，采用了随机、对 照的方法，对 60 例冠心病心绞痛患者进行多方位临床观察。随机分为治疗 组和对照组，治疗组给予西药常规的基础上加服通痹合剂治疗和对照组给予 西药常规治疗。疗程为 4 周，治疗前后检测 TNF- a、IL-6 水平和心电图(ECG)。 结果 1.两组患者治疗后心绞痛疗效及中医证候疗效均优于治疗前；组 间比较显示治疗组均优于对照组，可以认为两组具有显著性差异(P＜0.05)； 2.两组治疗后 ECG 与治疗前比较均有所改善，组间比较无显著性差异(P＞ 0.05)；3.两组在硝酸甘油减停率有显著性差异(P＜0.05)，可认为治疗组疗 效优于对照组；4.两组患者治疗后 TNF- a、IL-6 水平显著性降低，与治疗 前比具有显著性差异(P＜0.05)。组间的比较显示治疗组优于对照组，具有 显著性差异(P＜0.05)。 结论 通痹合剂无毒副作用，安全可靠，可以明显改善冠心病心绞痛患 者的临床症状，降低血中的 TNF- a、IL-6，改善内皮功能，从而改善心肌供 血，提高患者生活质量，是治疗冠心病心绞痛安全有效的药物。 关键词 冠心病；心绞痛；肿瘤坏死因子- a (TNF-a)、白介素-6（IL-6）； 通痹合剂 The clinical research of curative effect of change of levels of serum TNF-a、IL-6 TongBi Mixture on patients of coronary heart disease (CHD) suffering ABSTRACT Objective To observe the mixture of coronary artery disease angina patients polio-free, serum tumor necrosis factor (TNF-a ), interleukin (IL-6)levels of influence, illustrate the party,improving cardiovascular risk factors affecting link, much more patient treatment of coronary heart disease, angina, discuss the role of traditional Chinese medicine in the treatment of coronary heart disease mechanisms.  Methods  This experiment using clinical observation and theory  research of combining the methods, the use of a randomized, controlled method of 60 cases of coronary heart disease, angina, patients with clinical observation is analyzed. Randomly divided into treatment group and control group, the treatment group give western medicine based on conventional attack with clothing and controls the mixture to western medicine treatment of conventional treatment. Treatment for 4 weeks, before and after the treatment detection TNF-a, IL-6 level and electrocardiogram (ECG).  Results  1. The two groups of patients after treatment and effect of  angina were superior efficacy syndromes before treatment; Groups in treatment group comparison shows are better than the contro